Comments
Loading...

Vincerx Pharma Analyst Ratings

VINCNASDAQ
Logo brought to you by Benzinga Data
$0.6051
-0.05-8.29%
At close: -
$0.6170
0.011.97%
After Hours: 7:58 PM EDT
Consensus Rating1
Buy
Highest Price Target1
$6.00
Lowest Price Target1
$2.00
Consensus Price Target1
$4.00

Vincerx Pharma Analyst Ratings and Price Targets | NASDAQ:VINC | Benzinga

Vincerx Pharma Corp has a consensus price target of $567.61 based on the ratings of 38 analysts. The high is $1350 issued by HSBC on May 10, 2024<. The low is $100 issued by Deutsche Bank on August 5, 2024. The 3 most-recent analyst ratings were released by New Street Research, Goldman Sachs, and Deutsche Bank on August 6, 2024, August 5, 2024, and August 5, 2024, respectively. With an average price target of $118.33 between New Street Research, Goldman Sachs, and Deutsche Bank, there's an implied 0.21% upside for Vincerx Pharma Corp from these most-recent analyst ratings.

Analyst Trends and Forecast
1
Oct 24
Buy
Hold
Sell
Strong Sell
Analyst Rating and Forecast
12345
4.3
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

Leerink Partners
Chardan Capital
SVB Leerink
B. Riley Securities

1calculated from analyst ratings

Analyst Ratings for Vincerx Pharma

Buy NowGet Alert
10/08/2024Buy NowLeerink Partners
Jonathan Chang38%
$80 → $40MaintainsOutperformGet Alert
04/09/2024Buy NowCantor Fitzgerald
Li Watsek39%
Reiterates → OverweightGet Alert
04/01/2024Buy NowCantor Fitzgerald
Li Watsek39%
Reiterates → OverweightGet Alert
09/07/2023Buy NowCantor Fitzgerald
Li Watsek39%
→ $100ReiteratesOverweight → OverweightGet Alert
11/17/2022Buy NowChardan Capital
Matthew Barcus54%
$80 → $60MaintainsBuyGet Alert
08/12/2022Buy NowSVB Leerink
Jonathan Chang38%
$120 → $100MaintainsOutperformGet Alert
06/08/2022Buy NowCantor Fitzgerald
Li Watsek39%
$440 → $160MaintainsOverweightGet Alert
06/07/2022Buy NowB. Riley Securities
Kalpit Patel37%
$240 → $120MaintainsBuyGet Alert
06/07/2022Buy NowChardan Capital
Matthew Barcus54%
$220 → $80MaintainsBuyGet Alert
06/07/2022Buy NowSVB Leerink
Jonathan Chang38%
$380 → $120MaintainsOutperformGet Alert
05/13/2022Buy NowChardan Capital
Matthew Barcus54%
$280 → $220MaintainsBuyGet Alert
05/13/2022Buy NowSVB Leerink
Jonathan Chang38%
$400 → $380MaintainsOutperformGet Alert

FAQ

Q

What is the target price for Vincerx Pharma (VINC) stock?

A

The latest price target for Vincerx Pharma (NASDAQ:VINC) was reported by Leerink Partners on October 8, 2024. The analyst firm set a price target for $2.00 expecting VINC to rise to within 12 months (a possible 224.15% upside). 2 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Vincerx Pharma (VINC)?

A

The latest analyst rating for Vincerx Pharma (NASDAQ:VINC) was provided by Leerink Partners, and Vincerx Pharma maintained their outperform rating.

Q

When was the last upgrade for Vincerx Pharma (VINC)?

A

There is no last upgrade for Vincerx Pharma

Q

When was the last downgrade for Vincerx Pharma (VINC)?

A

There is no last downgrade for Vincerx Pharma.

Q

When is the next analyst rating going to be posted or updated for Vincerx Pharma (VINC)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Vincerx Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Vincerx Pharma was filed on October 8, 2024 so you should expect the next rating to be made available sometime around October 8, 2025.

Q

Is the Analyst Rating Vincerx Pharma (VINC) correct?

A

While ratings are subjective and will change, the latest Vincerx Pharma (VINC) rating was a maintained with a price target of $4.00 to $2.00. The current price Vincerx Pharma (VINC) is trading at is $0.62, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch